Monoclonan Antlbodies (MABS)

Home Products Monoclonan Antlbodies (MABS)
Sr. No. Product Name Cas No.
1 Adalimumab 331731-18-1
2 Aducanumab 1384260-65-4
3 Aflibercept 845771-78-0
4 Alemtuzumab 216503-57-0
5 Alirocumab 1245916-14-6
6 Atezolizumab 1380723-44-3
7 Benralizumab 1044511-01-4
8 Bevacizumab 216974-75-3
9 Casirivimab N/A
10 Cetuximab 205923-56-4
11 Daratumumab 945721-28-8
12 Denosumab 615258-40-7
13 Dulaglutide 923950-08-7
14 Dupliumab 1190264-60-8
15 Eculizumab 219685-50-4
16 Efmoroctocog alfa 1270012-79-7
17 Emicizumab 1610943-06-0
18 Evolocumab 1256937-27-5
19 Imdevimab N/A
20 Infliximab 170277-31-3
21 Ipilimumab 477202-00-9
22 Lecanemab 1260393-98-3
23 Mepolizumab 196078-29-2
24 Natalizumab 189261-10-7
25 Nivolumab 946414-94-4
26 Ocrelizumab 637334-45-3
27 Omalizumab 242138-07-4
28 Panitumumab 339177-26-3
29 Pembrolimumab 1374853-91-4
30 Pertuzumab 380610-27-5
31 Ramucirumab 947687-13-0
32 Risankizumab N/A
33 Rituximab 174722-31-7
34 Sarilumab 1189541-98-7
35 Secukinumab 875356-43-7
36 Tezepelumab 1572943-04-4
37 Tocilizumab 375823-41-9
38 Trastuzumab 180288-69-1
39 Trastuzumab Deruxtecan 1826843-81-5
40 Trastuzumab emtansine 1018448-65-1
41 Ustekinumab 815610-63-0
42 Vedolizumab 943609-66-3

Disclaimer: Some products listed are currently under development; therefore, detailed information may not be available at this stage. Products that are subject to existing patent protection are offered solely for purposes reasonably related to research, development, and regulatory submission to the relevant Health Authorities, in accordance with applicable laws governing the manufacture, use, and sale of Active Pharmaceutical Ingredients.